Sign in
← Database
AMPK Activator

O-304

Shop · Omnichems ↗Buy · Disguised Alpha ↗
Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

An experimental small-molecule direct activator of AMPK studied mainly in preclinical models, with very limited early human data.

How it works

O-304 is a research compound designed to switch on an enzyme called AMPK, which acts as the body's cellular fuel gauge. When cells run low on energy, AMPK normally turns on to restore balance by burning fuel and easing energy-demanding processes. O-304 attempts to mimic that low-energy signal directly, even when the cell is not actually depleted.

The interest behind O-304 is largely metabolic. By nudging AMPK on, researchers hope to improve how cells take up and use glucose, encourage fat burning, and improve blood flow in small vessels. Much of this thinking comes from animal studies and basic cell experiments rather than large human trials.

It is important to be clear that O-304 is investigational and not an approved drug. Human experience with it is very limited and early, so claims about real-world benefits or long-term safety remain unproven. It should be viewed as an experimental compound under study, not an established therapy.

Mechanism · Detailed Analysis
Molecular targetO-304 is described as a direct, pan-AMPK activator, meaning it binds and stabilizes the AMP-activated protein kinase complex rather than acting indirectly through upstream changes in cellular AMP/ATP ratios. AMPK is a heterotrimeric enzyme composed of catalytic alpha and regulatory beta and gamma subunits; direct activators of this class are thought to engage allosteric sites and promote the active, phosphorylated state of the kinase.
Signaling & downstream effectsActivated AMPK shifts cellular metabolism from anabolic toward catabolic programs. Downstream consequences described in preclinical work include increased glucose uptake via GLUT4 translocation in skeletal muscle, enhanced fatty-acid oxidation through inhibition of acetyl-CoA carboxylase, suppression of hepatic gluconeogenesis, and effects on the vascular endothelium that may support microvascular perfusion. These effects are largely characterized in animal and cell models.
PharmacokineticsO-304 is an orally studied small molecule in preclinical and early-stage settings. Detailed, well-established human pharmacokinetic parameters such as absorption, distribution, half-life, and clearance are not robustly defined in the public literature, reflecting how early its clinical evaluation is.
CaveatsEvidence for O-304 is overwhelmingly preclinical or very early human, so efficacy and long-term safety in people are unproven. It is investigational and not approved by any major regulator for clinical use. Direct AMPK activation has broad, tissue-wide effects, and the consequences of chronic activation in humans are not well understood. This entry is educational and is not a recommendation to use the compound.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.